Navigation Links
BioDelivery Sciences to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/25/2013

RALEIGH, N.C., Nov. 25, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 25th Annual Piper Jaffray Healthcare Conference.  The presentation is scheduled for Wednesday, December 4, 2013 at 1:00 p.m. Eastern Time at The New York Palace.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO )

BDSI submitted a New Drug Application (NDA) for BUNAVAIL for the treatment of opioid dependence, and based on timelines established by the Prescription Drug User Fee Act (PDUFA), the review of the BUNAVAIL NDA is expected to be completed by June 7, 2014.  Dr. Sirgo will be providing an update on BUNAVAIL commercial options and the anticipated market opportunity.

Additionally, Dr. Sirgo will provide an update on the progress made by BDSI and its commercial partner, Endo Health Solutions, with the ongoing Phase 3 clinical program for BEMA Buprenorphine for the treatment of chronic pain along with updated plans for the initiation of the pivotal clinical trial program for Clonidine Topical Gel for the treatment of painful diabetic neuropathy.

The presentation will be webcast live and can be accessed at www.bdsi.com.  For those who are not available to listen to the live broadcast, a replay of the webcast will be available on the BDSI website.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. 

BDSI's pain franchise consists of three products, two of which utilize the patented BioErodible MucoAdhesive (BEMA) drug delivery technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, E.U. (where it is marketed as BREAKYL) and Taiwan (where it is marketed as PAINKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.). 

BEMA Buprenorphine is in Phase 3 clinical trials for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo.  Clonidine Topical Gel for the treatment of painful diabetic neuropathy is currently in Phase 2 development.

An NDA for BUNAVAIL, a BEMA formulation of buprenorphine used in combination with naloxone, is currently under review for the maintenance treatment of opioid dependence and has a PDUFA date of June 7, 2014.

BDSI's headquarters is located in Raleigh, North Carolina.  For more information visit www.bdsi.com.

Cautionary Note on Forward-Looking Statements

This press release, the presentation referred to herein, and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submissions for, and FDA review of, the Company's products in development, as well as the outcomes of the Company's commercial plans) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences logo and BUNAVAIL™ are trademarks owned by BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL™ is a trademark owned by Meda Pharma GmbH & Co. KG.  PAINKYLTM is a trademark owned by TTY Biopharm.  All other trademarks and tradenames are owned by their respective owners.

© BioDelivery Sciences International, Inc.  All rights reserved


'/>"/>
SOURCE BioDelivery Sciences International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
2. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
3. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
4. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
5. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
6. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
7. BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
8. BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. BioDelivery Sciences Announces $40 Million Registered Financing
10. BioDelivery Sciences Announces Completion of BNX Safety Study
11. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... DPLO ) is pleased to announce the promotion of Paul Urick to ... To learn more about our Diplomat executive ... ... ... In his redefined role at ...
(Date:2/12/2016)... --  HeartWare International, Inc . (NASDAQ: HTWR ) ... its financial results for the three and 12 months ... at 8:00 a.m. ET.  The company plans to release ... webcast.  On the conference call and webcast, management will ... quarter and business outlook.   --> ...
(Date:2/12/2016)... Feb. 12, 2016  Sequent Medical, Inc. announced today ... to evaluate the safety and effectiveness of the WEB™ ... ruptured intracranial aneurysms.  Prof Laurent Spelle , MD, ... Paris, France and Principal Investigator of ... France and Germany.  Although patients with ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... ... Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to introduce and ... U.S. universities who will draw from Siemens’ deep knowledge of product development ...
(Date:2/12/2016)... , ... February 12, 2016 , ... As a former ... schedule, a demanding job, and no time to decompress, Rabinowitz found herself drawn to ... to meditation for its impact on her life, implementing a 20-minute-per-day meditation practice with ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Every winter, ... , This winter the West Penn Burn Center, part of the Allegheny ... #1, to bring you the “Space Heaters Need Space” campaign. , ...
(Date:2/12/2016)... ... February 12, 2016 , ... Erlanger Agency has announced a ... OH area. The latest campaign focuses on the fight against breast cancer, fundraising for ... being accepted here . , Carmen is a loving single mother of two ...
(Date:2/12/2016)... ... February 12, 2016 , ... J Thomas & ... continuing it’s commitment to act as Agents of Change in the community, announces ... area homeless families to fulfill immediate needs and help them move into permanent ...
Breaking Medicine News(10 mins):